New Report from MGA Examines the One-Year Cost Savings Lost Due to Patent Thickets MGA has released a new report today for the Coalition for Affordable Prescription Drugs (CAPD), “Patent Thickets and Lost Drug Savings.” This report, authored by Alex Brill...
New MGA Analysis of Biosimilar Coverage in Commercial Medical Benefit A new MGA white paper from CEO Alex Brill and Principal Christy Robinson shows a positive outlook for biosimilar coverage in the commercial medical benefit. While patients and physicians play a role...
Updated MGA Report Presents Biosimilar Market Opportunities in Ophthalmology MGA releases an updated report, “Biosimilar Market Opportunities in Ophthalmology.” Authored by founder and CEO Alex Brill, the report examines the economics of biologic drugs for...
MGA Releases Economic Impact Report for Multinational Pharmaceutical Company In a newly released report, MGA highlights the broad economic impact of Otsuka Pharmaceutical in the U.S. operations. A leader in mental health and nephrology treatments, Otsuka offers both...
New MGA Report Presents Biosimilar Market Opportunities in Ophthalmology MGA releases a new report, “Biosimilar Market Opportunities in Ophthalmology.” Authored by founder and CEO Alex Brill, the report examines current trends and economics in the ophthalmology...
Alex Brill to FTC: Claims That PBMs Raise Drug Prices are Unfounded MGA’s Alex Brill submitted a letter in response to a request for information from the Federal Trade Commission. The FTC was looking for information regarding the business practices of pharmacy benefit...
